uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Section of Nuclear Medicine and PET.
Show others and affiliations
2013 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 19, no 15, 4163-4173 p.Article in journal, Meeting abstract (Refereed) Published
Abstract [en]


Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomography (PET) and a microdose of radiolabeled docetaxel ([11C]docetaxel). The objective of this study was to investigate whether a [11C]docetaxel PET microdosing study could predict tumor uptake of therapeutic doses of docetaxel.

Experimental Design:

Docetaxel-naïve lung cancer patients underwent 2 [11C]docetaxel PET scans; one after bolus injection of [11C]docetaxel and another during combined infusion of [11C]docetaxel and a therapeutic dose of docetaxel (75 mg·m−2). Compartmental and spectral analyses were used to quantify [11C]docetaxel tumor kinetics. [11C]docetaxel PET measurements were used to estimate the area under the curve (AUC) of docetaxel in tumors. Tumor response was evaluated using computed tomography scans.


Net rates of influx (Ki) of [11C]docetaxel in tumors were comparable during microdosing and therapeutic scans. [11C]docetaxel AUCTumor during the therapeutic scan could be predicted reliably using an impulse response function derived from the microdosing scan together with the plasma curve of [11C]docetaxel during the therapeutic scan. At 90 minutes, the accumulated amount of docetaxel in tumors was less than 1% of the total infused dose of docetaxel. [11C]docetaxel Ki derived from the microdosing scan correlated with AUCTumor of docetaxel (Spearman ρ = 0.715; P = 0.004) during the therapeutic scan and with tumor response to docetaxel therapy (Spearman ρ = −0.800; P = 0.010).


Microdosing data of [11C]docetaxel PET can be used to predict tumor uptake of docetaxel during chemotherapy. The present study provides a framework for investigating the PET microdosing concept for radiolabeled anticancer drugs in patients.

Place, publisher, year, edition, pages
2013. Vol. 19, no 15, 4163-4173 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-206563DOI: 10.1158/1078-0432.CCR-12-3779ISI: 000322598900016OAI: oai:DiVA.org:uu-206563DiVA: diva2:644913
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, NOV 06-09, 2012, Dublin, IRELAND
Available from: 2013-09-02 Created: 2013-09-02 Last updated: 2015-09-18

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Lubberink, MarkEriksson, Jonas
By organisation
Section of Nuclear Medicine and PET
In the same journal
Clinical Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 190 hits
ReferencesLink to record
Permanent link

Direct link